Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 2

Chemotherapy regimens that were administered as first-line treatment.

First-line chemotherapy regimen	N	%
Nab-paclitaxel/gemcitabine	113	58.5
Gemcitabine	16	8.3
Gemcitabine/5-fluorouracil	1	0.5
Gemcitabine/oxaliplatin	5	2.6
Gemcitabine/cisplatin	3	1.6
Gemcitabine/carboplatin	1	0.5
Gemcitabine/erlotinib	1	0.5
Gemcitabine/temsirolimus	1	0.5
FOLFIRINOX	36	18.7
CAPOXIRI	6	3.1
FOLFOX	4	2.1
CAPOX	2	1.0
FOLFIRI	1	0.5
CDDP/LV/5-fluorouracil	2	1.0
Cisplatin/etoposide	1	0.5
Total	193	100.0

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; CDDP, cisplatin; FOLFIRI, irinotecan/leucovorin/5-fluorouracil; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil.